Dr. Eldon’s extensive experience in clinical pharmacology, PK/PD, and pharmacometrics make him an excellent resource for our clients in the preclinical and clinical drug development phases.
ROCHELLE, VIRGINIA (PRWEB)
August 07, 2017
NDA Partners Chairman Carl Peck, MD, announced today that Dr. Michael A. Eldon, the former Vice President of Clinical Pharmacology at Nektar Therapeutics, and a clinical pharmacology, pharmacokinetics/pharmacodynamics and pharmacometrics expert with more than thirty-five years of experience in the pharmaceutical industry, has joined the firm as an Expert Consultant.
As Vice President of Clinical Pharmacology at Nektar Therapeutics, Dr. Eldon was responsible for clinical and preclinical pharmacokinetics, ADME, pharmacometrics and systems biology in drug development and discovery.
Prior to Nektar, Dr. Eldon worked at Parke-Davis Pharmaceutical Research where he participated in the development and registration of Lipitor (atorvastatin), Neurontin (gabapentin), Rezulin (troglitazone), Lyrica (pregabalin), Pro-Air (procaterol), Lopid (gemfibrozil), Loestrin (oral contraceptive), Estrostep (oral contraceptive), Procanbid (procainamide extended release), FemPatch (transdermal estradiol), Cerebyx (fosphenytoin), Penetrex (enoxacin), Zagam (sparfloxacin) and Nitrostat (nitroglycerin) stabilized tablets. While at Nektar, he participated in the discovery, development, and registration of Movantik and Exubera (rH insulin for inhalation); and the discovery and preclinical and clinical development of other Nektar proprietary products including Onzeald (etirinotecan pegol), NKTR-181, and NKTR-214.
“Dr. Eldon’s extensive experience in clinical pharmacology, PK/PD, and pharmacometrics make him an excellent resource for our clients in the preclinical and clinical drug development phases,” said Dr. Carl Peck. “We are very pleased he has joined NDA Partners.”
Dr. Eldon earned his doctorate degree in Biopharmaceutics and Pharmacokinetics and a Bachelors of Science degree in Pharmacy from the University of Cincinnati. He is a member of several pharmaceutical societies, is a Fellow of the American College of Clinical Pharmacology, and has authored over 150 scientific articles and presentations.
About NDA Partners
NDA Partners is a strategy…